Abstract
The statins are the most important group of drugs for lipid-lowering therapy in the prevention of coronary heart disease. Greater reductions in LDL-cholesterol appear to be associated with greater benefits but the clinical efficacy and safety of statin treatment varies considerably from person to person because of a combination of phenotypic and genotypic factors. Pharmacogenetic studies have investigated the relationship between common genetic variants and the lipid responses to statin therapy and adverse events, and some candidate genes related to the pharmacodynamics and pharmacokinetics of different statins have been identified. Some of these genetic variants show a different frequency in different ethnic groups. This field of pharmacogenetic research is receiving considerable attention and many new findings have been reported recently. Pharmacogenetic and pharmacogenomic studies of statin therapy are likely to provide a better understanding of the effects of these drugs and to help with prediction of the most appropriate drug and dosage for each individual and whether the addition or substitution of other lipid modifying drugs may be necessary to achieve the most safe and effective prevention of coronary heart disease.
Keywords: Coronary heart disease, ethnic differences, HMG-CoA reductase inhibitors, LDL-cholesterol, pharmacogenetics
Current Pharmacogenomics and Personalized Medicine
Title: Pharmacogenetics of HMG-CoA Reductase Inhibitors: Optimizing the Prevention of Coronary Heart Disease
Volume: 7 Issue: 1
Author(s): M. Hu, V. W.L. Mak, T. T.W. Chu, M. M.Y. Waye and B. Tomlinson
Affiliation:
Keywords: Coronary heart disease, ethnic differences, HMG-CoA reductase inhibitors, LDL-cholesterol, pharmacogenetics
Abstract: The statins are the most important group of drugs for lipid-lowering therapy in the prevention of coronary heart disease. Greater reductions in LDL-cholesterol appear to be associated with greater benefits but the clinical efficacy and safety of statin treatment varies considerably from person to person because of a combination of phenotypic and genotypic factors. Pharmacogenetic studies have investigated the relationship between common genetic variants and the lipid responses to statin therapy and adverse events, and some candidate genes related to the pharmacodynamics and pharmacokinetics of different statins have been identified. Some of these genetic variants show a different frequency in different ethnic groups. This field of pharmacogenetic research is receiving considerable attention and many new findings have been reported recently. Pharmacogenetic and pharmacogenomic studies of statin therapy are likely to provide a better understanding of the effects of these drugs and to help with prediction of the most appropriate drug and dosage for each individual and whether the addition or substitution of other lipid modifying drugs may be necessary to achieve the most safe and effective prevention of coronary heart disease.
Export Options
About this article
Cite this article as:
Hu M., Mak W.L. V., Chu T.W. T., Waye M.Y. M. and Tomlinson B., Pharmacogenetics of HMG-CoA Reductase Inhibitors: Optimizing the Prevention of Coronary Heart Disease, Current Pharmacogenomics and Personalized Medicine 2009; 7 (1) . https://dx.doi.org/10.2174/187569209787582349
DOI https://dx.doi.org/10.2174/187569209787582349 |
Print ISSN 1875-6921 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6913 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Gene Therapy Approaches for Cardiovascular Diseases
Current Gene Therapy Does Daily Dialysis Improve Hypertension in Chronic Haemodialysis Patients?
Current Hypertension Reviews Platelet in Progression of Atherosclerosis: A Potential Target in Diabetic Patients
Current Diabetes Reviews The Development of Antibody-based Immunotherapy for Methamphetamine Abuse: Immunization, and Virus-Mediated Gene Transfer Approaches
Current Gene Therapy The Metabolic Syndrome and Vascular Disease in Asia
Cardiovascular & Hematological Disorders-Drug Targets Disrupted White Matter Networks from Subjective Memory Impairment to Amnestic Mild Cognitive Impairment
Current Alzheimer Research Molecular Basis of Antiretroviral Drugs-Associated Long-Term Toxicity: How Bad can Good Drugs Be?
Current Medicinal Chemistry - Anti-Infective Agents Virus Vasculopathy and Stroke: An Under-Recognized Cause and Treatment Target
Infectious Disorders - Drug Targets Is there any Additional Prognostic Value of Central Blood Pressure Wave Forms Beyond Peripheral Blood Pressure?
Current Pharmaceutical Design Sex-Related Differences in QTc Effects Potential of Drugs
Reviews on Recent Clinical Trials Mechanical Support in Cardiogenic Shock Complicating Acute Coronary Syndrome: Ready for Prime Time?
Current Vascular Pharmacology Biobanking in Atherosclerotic Disease, Opportunities and Pitfalls
Current Cardiology Reviews Peptide Receptor Radionuclide Therapy with Somatostatin Analogues in Neuroendocrine Tumors
Anti-Cancer Agents in Medicinal Chemistry Clinical Relevance of Postprandial Lipaemia
Current Medicinal Chemistry Pattern of Medication Use Among Older Inpatients in Seven Hospitals in Italy: Results from the Criteria to Assess Appropriate Medication Use Among Elderly Complex Patients (CRIME) Project
Current Drug Safety Future Preventive and Therapeutic Targets for Transfusion-Related Acute Lung Injury
Current Pharmaceutical Design Hyper-Coagulable Profile with Elevated Pro-Thrombotic Biomarkers and Increased Cerebro- and Cardio-Vascular Disease Risk Exist Among Healthy Dyslipidemic Women
Current Neurovascular Research Renal Endothelial Dysfunction in Diabetic Nephropathy
Cardiovascular & Hematological Disorders-Drug Targets Roles of miRNA in Cardiovascular Development and Dysfunction
Current Medicinal Chemistry Nutraceuticals for Metabolic Syndrome Management: From Laboratory to Benchside
Current Vascular Pharmacology